El estado protrombótico en los pacientes con cáncer

Translated title of the contribution: The protrombotic state in patients with cancer

Lluvia S. Sosa-Quintero, Ivette L. Carrasco-Martínez, Ignacio Mariscal-Ramírez, Eduardo E. García-Luna, Arnulfo H. Nava-Zavala, Benjamín Rubio-Jurado*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Cancer is an acquired prothrombotic state with an increased risk of thrombosis. Thromboembolic complications are the second cause of death, and pulmonary thromboembolism counts for about 50% of necropsies of cancer patients. In these patients, the prothrombotic state is a subclinical condition that is detected by the presence of an increase in serum fibrinogen levels, fibrin degradation products, coagulation factors such as factor V, VII, IX, X, and thrombocytosis, among others. In the cancer prothrombotic state, the biological mechanisms modify Virchow's triad elements, and cell activity, modify proteins, and neoplastic cells produce procoagulant molecules, fibrinolytic, and proinflammatory cytokines. The Khorana predictive model, which includes the measurement of biomarkers such as D dimer and P selectin, allows stratifying clinical risk. Prevention of venous thromboembolism in patients at higher risk could improve the response to treatment and survival. Therefore, properly designed studies should clarify the effect of thromboprophylaxis in these patients.

Translated title of the contributionThe protrombotic state in patients with cancer
Original languageSpanish
Pages (from-to)26-34
Number of pages9
JournalGaceta Mexicana de Oncologia
Issue number1
Publication statusPublished - Jan 2021

Bibliographical note

Publisher Copyright:
© 2021 Publicaciones Permanyer. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'The protrombotic state in patients with cancer'. Together they form a unique fingerprint.

Cite this